Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod 5% Cream for Nodular BCC After Curettage
NCT00314756Phase 4Completed
- Sponsor
- Wake Forest University
- Start
- Mar 2005
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imiquimod in basal cell carcinoma (nodular) (BCC), sponsored by Wake Forest University. Primary endpoint: Histologic Clearance of Basal Cell Carcinoma at 12 weeks. Started Mar 2005; status: completed.
02
Drugs
imiquimod
03
Conditions
basal cell carcinoma (nodular) (BCC)
Beyond the preview
Go deeper on NCT00314756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00314756.